Day: December 18, 2023

Reminder of Upcoming Delisting from Euronext Milan and Single Listing on the New York Stock Exchange

Basildon, December 18, 2023 Further to the announcements made by CNH Industrial N.V. (NYSE: CNHI / MI: CNHI) on November 7, 2023, the Company hereby reminds its shareholders, pursuant to Articles 2.5.5 and 2.5.6 of the Rules of the Markets organized and managed by Borsa Italiana (Regolamento dei Mercati organizzati e gestiti da Borsa Italiana S.p.A.), of the delisting of the Company’s common shares from Euronext Milan with effect from January 2, 2024 (the “Date of Delisting”), as arranged by Borsa Italiana on November 7, 2023. CNH common shares will continue to be listed on Euronext Milan until the business day before the Date of Delisting, or December 29, 2023. The single listing on the New York Stock Exchange (NYSE) will therefore be effective starting from the Date of Delisting. Additional practical information regarding the delisting...

Continue reading

SKEL fjárfestingafélag hf: Buy-back Programme week 50

In week 50 2023, SKEL fjárfestingafélag hf. purchased in total 1,368,286 own shares for total amount of 18,519,111 ISK as follows: Date Time Purchased shares Price Purchase price Total own shares 11.12.2023 11:53:00 2,500    14    34,000    53,095,355    11.12.2023 13:48:00 435,786    14    5,883,111    53,531,141    13.12.2023 10:10:00 230,000    13    3,082,000    53,761,141    15.12.2023 14:50:00 700,000    14    9,520,000    54,461,141        1,368,286   18,519,111 54,461,141 The execution of the buy-back programme is in accordance with Chapter VIII of the Company Act No 2/1995, Article 5 of the Regulation of the European parliament and of the Council (EU) on Market Fraud No. 60/2021, the Commissions Delegated Regulation No. 2016/1052 and the Act on Actions against Market Fraud No. 60/2021. Before the...

Continue reading

Sydbank share buyback programme: transactions in week 50

         Company Announcement No 44/2023 Peberlyk 46200 AabenraaDenmark Tel +45 74 37 37 37Fax +45 74 37 35 36 Sydbank A/SCVR No DK 12626509, Aabenraasydbank.dk 18 December 2023   Dear Sirs Sydbank share buyback programme: transactions in week 50On 6 July 2023 Sydbank announced a share buyback programme of DKK 600m. The share buyback programme commenced on 10 July 2023 and will be completed by 31 January 2024. The purpose of the share buyback programme is to reduce the share capital of Sydbank and the programme is executed in compliance with the provisions of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 and Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016, collectively referred to as the Safe Harbour rules. The following transactions have been made under the share buyback...

Continue reading

Regenx Announces Proposed Debenture Offering With a $750,000 Lead Order

EDMONTON, Alberta, Dec. 18, 2023 (GLOBE NEWSWIRE) — Regenx Tech Corp., (the “Corporation” or “Regenx”) (TSXV: RGX) (OTCQB: RGXT) (FSE: YRS WKN: A2DSW3) announced today its intention to complete a non-brokered private placement offering of unsecured convertible debentures (“Debentures”) in the principal amount of up to $1.5 Million (the “Private Placement”) with a lead order in place for $750,000. The Debentures will bear interest at the rate of fifteen percent (15%) per annum, payable on the maturity date and will mature on December 31, 2025. The Debentures will be convertible at the holder’s option into common shares of the Corporation (“Common Shares”) at a conversion price of: (i) $0.05 per Common Share until the date that is one (1) year from the closing date; and (ii) $0.105 per Common Share for the...

Continue reading

NBPE Announces November 2023 NAV Estimate

THE INFORMATION CONTAINED HEREIN IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO AUSTRALIA, CANADA, ITALY, DENMARK, JAPAN, THE UNITED STATES, OR TO ANY NATIONAL OF SUCH JURISDICTIONS NBPE Announces November 2023 NAV Estimate 18 December 2023 NB Private Equity Partners (NBPE), the $1.3bn, FTSE 250, listed private equity investment company managed by Neuberger Berman, today releases its 30 November 2023 monthly NAV estimate. Highlights (30 November 2023) NAV per share of $27.70 (£21.88), an increase of 2.3% during the month Monthly NAV driven by an increase in the value of quoted holdings, positive foreign exchange movements and the receipt of additional Q3 private valuation information Year to date constant currency private valuations are up 5.5% Realisation activity year to date of $118 million of proceeds received and...

Continue reading

Guar Gum Market to Worth USD 2.01 Billion by 2030 | Exclusive Report by Fortune Business Insights™

Key companies covered in guar gum market are Cargill Corporation (U.S.), Ingredion Incorporated (U.S.), ALTRAFINE GUMS (India), VIKAS WSP LTD. (India), NEELKANTH POLYMERS (India) , ASHAPURA PROTEINS LTD. (India) , Hindustan Gum & Chemicals Ltd. (India), Shree Ram India Gums (India), India Glycols Ltd. (India) and more players profiled. Guar Gum Market Guar Gum Market Size Pune, India, Dec. 18, 2023 (GLOBE NEWSWIRE) — The guar gum market size was valued at USD 1.17 billion in 2022 and is projected to grow from USD 1.25 billion in 2023 to USD 2.01 billion by 2030, exhibiting a CAGR of 7.05% during 2023-2030. Guar gum, known as cluster bean gum, guaran gum, and goma guar, is a natural galactomannan polysaccharide extracted from the guar plant’s endosperm. These guar crops or plants are native to South Asian nations,...

Continue reading

VGP Unveils New € 1.5 Billion 50:50 Joint Venture

Regulated Information – Inside Information Antwerp, Belgium – 18 December 2023, 7:00 am: VGP NV (“VGP”, or “the Group”), a European provider of high-quality logistics and semi-industrial real estate, is pleased to announce the establishment of a new 50:50 Joint Venture named “Saga” with Areim, an independent fund manager and property owner headquartered in Stockholm. This Joint Venture targets € 1.5 billion of gross asset value with a loan-to-value ratio of approximately 35%. It foresees a five year investment period and has a total term of ten years, with several extension options. The Saga Joint Venture will focus exclusively on key European markets, including France, Germany, The Czech Republic, Slovakia, and Hungary. The financing of Areim’s share in the Joint Venture comes from a recently closed fund, Areim Pan-European...

Continue reading

TGS Secures Two-Month Proprietary OBN Data Acquisition Contract in the Gulf of Mexico

OSLO, Norway (18 December 2023) – TGS, the leading global provider of energy data and intelligence, has been awarded a two-month proprietary Ocean Bottom Node (OBN) data acquisition contract in the Gulf of Mexico. The project’s acquisition will start in Q1 2024. Kristian Johansen, CEO at TGS, commented: “This project highlights the key role OBN data plays in this vital basin. OBN technology provides the essential data needed to visualize and understand the intricate structures within the Gulf of Mexico, enabling our clients to make well-informed, data-driven decisions in their field development strategies.” As the industry evolves, the adoption of OBN technology brings forth a myriad of benefits for both the energy sector and its stakeholders. By employing OBN technology, TGS ensures a more comprehensive and accurate understanding of subsurface...

Continue reading

Ultimovacs Announces Completion of Exploratory Phase I TENDU Study of TET Vaccine Technology Platform Meeting the Primary Endpoint

  Dose-escalation, first-in-human Phase I trial showed good safety and tolerability across all dose-cohorts, meeting the primary endpoint Data included observations of immune activation with vaccine specific T cell responses, meeting the secondary endpoint In addition to the trial results, advancements in preclinical research, technology development and product manufacturing provide a valuable foundation for the future development of the TET technology platform and TET-based vaccine candidates   Oslo, December 18, 2023: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines, today announced the conclusion of the exploratory Phase I TENDU study (NCT04701021) of the company’s vaccine technology platform, Tetanus-Epitope Targeting (TET), in patients with prostate cancer....

Continue reading

MDxHealth Announces Completion of Transition to Single Listing on Nasdaq

NEWS RELEASE – REGULATED INFORMATIONDECEMBER 18, 2023, 1:00 AM ET / 07:00 AM CET              MDxHealth Announces Completion of Transition to Single Listing on Nasdaq IRVINE, CA, and HERSTAL, BELGIUM – December 18, 2023 – MDxHealth SA (NASDAQ/Euronext Brussels: MDXH) (the “Company” or “mdxhealth”), a commercial-stage precision diagnostics company, today announces the completion of its transition to a single listing on Nasdaq. In accordance with prior announcements made by the Company and the corporate event notice issued by Euronext on December 6, 2023, the last trading day of the Company’s ordinary shares (the “Shares”) on the regulated market of Euronext Brussels was December 15, 2023. Trading of the Shares on Euronext Brussels will not resume and the Shares will, as from today, be de-listed...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.